DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,140,986 | +11.4% | 12,660 | +7.8% | 0.25% | +19.4% |
| Q2 2023 | $2,819,319 | -6.1% | 11,747 | -1.4% | 0.21% | -11.3% |
| Q1 2023 | $3,003,854 | +11.4% | 11,918 | +17.3% | 0.24% | +2.1% |
| Q4 2022 | $2,696,710 | +4.5% | 10,160 | +1.7% | 0.23% | +3.6% |
| Q3 2022 | $2,580,000 | -10.8% | 9,990 | -12.4% | 0.22% | -3.4% |
| Q2 2022 | $2,892,000 | -16.4% | 11,406 | -3.3% | 0.23% | +1.3% |
| Q1 2022 | $3,460,000 | -11.3% | 11,795 | -0.5% | 0.23% | -4.6% |
| Q4 2021 | $3,900,000 | +1.8% | 11,855 | -5.8% | 0.24% | -4.4% |
| Q3 2021 | $3,830,000 | +10.2% | 12,581 | -2.8% | 0.25% | +13.0% |
| Q2 2021 | $3,475,000 | +0.4% | 12,947 | -15.8% | 0.22% | -17.1% |
| Q1 2021 | $3,462,000 | -39.5% | 15,381 | -40.3% | 0.27% | -44.2% |
| Q4 2020 | $5,721,000 | -0.1% | 25,753 | -3.1% | 0.48% | -11.1% |
| Q3 2020 | $5,724,000 | +18.6% | 26,580 | -2.6% | 0.54% | +3.0% |
| Q2 2020 | $4,826,000 | +27.7% | 27,290 | -0.0% | 0.53% | +0.4% |
| Q1 2020 | $3,779,000 | -18.1% | 27,301 | -9.2% | 0.52% | +1.6% |
| Q4 2019 | $4,615,000 | +6.5% | 30,072 | +0.2% | 0.52% | -4.4% |
| Q3 2019 | $4,335,000 | -3.5% | 30,011 | -4.5% | 0.54% | -2.4% |
| Q2 2019 | $4,492,000 | -2.8% | 31,430 | -10.2% | 0.55% | -9.6% |
| Q1 2019 | $4,622,000 | +24.3% | 35,013 | -2.9% | 0.61% | +4.6% |
| Q4 2018 | $3,719,000 | -5.2% | 36,062 | -0.1% | 0.58% | +17.2% |
| Q3 2018 | $3,921,000 | -9.5% | 36,087 | -17.8% | 0.50% | -16.1% |
| Q2 2018 | $4,333,000 | +3.8% | 43,910 | +3.0% | 0.60% | -5.1% |
| Q1 2018 | $4,173,000 | +8.8% | 42,623 | +3.2% | 0.63% | +5.6% |
| Q4 2017 | $3,835,000 | +2.5% | 41,314 | -5.3% | 0.59% | +0.3% |
| Q3 2017 | $3,742,000 | +0.3% | 43,624 | -1.3% | 0.59% | -5.6% |
| Q2 2017 | $3,730,000 | +1.9% | 44,204 | 0.0% | 0.63% | -1.3% |
| Q1 2017 | $3,659,000 | +22.4% | 44,204 | +15.1% | 0.64% | +8.4% |
| Q4 2016 | $2,989,000 | -4.1% | 38,402 | -3.5% | 0.59% | -6.1% |
| Q3 2016 | $3,118,000 | -24.6% | 39,781 | -2.8% | 0.62% | -29.9% |
| Q2 2016 | $4,134,000 | +17.3% | 40,930 | +10.2% | 0.89% | +15.6% |
| Q1 2016 | $3,523,000 | -5.2% | 37,140 | -7.1% | 0.77% | -7.7% |
| Q4 2015 | $3,715,000 | +4.6% | 39,995 | -4.1% | 0.83% | -5.7% |
| Q3 2015 | $3,553,000 | -6.5% | 41,692 | -6.1% | 0.88% | +10.6% |
| Q2 2015 | $3,800,000 | -11.3% | 44,392 | -12.1% | 0.80% | -18.9% |
| Q1 2015 | $4,286,000 | -6.1% | 50,482 | -5.2% | 0.98% | -11.3% |
| Q4 2014 | $4,566,000 | -2.7% | 53,275 | -13.7% | 1.11% | -5.8% |
| Q3 2014 | $4,693,000 | -18.2% | 61,765 | -15.3% | 1.18% | -17.9% |
| Q2 2014 | $5,739,000 | +24.6% | 72,890 | +18.7% | 1.44% | +21.3% |
| Q1 2014 | $4,607,000 | +8.5% | 61,430 | +11.7% | 1.18% | +2.9% |
| Q4 2013 | $4,247,000 | +33.9% | 55,010 | +20.2% | 1.15% | +6.0% |
| Q3 2013 | $3,171,000 | +15.9% | 45,750 | +5.9% | 1.08% | +10.8% |
| Q2 2013 | $2,736,000 | – | 43,220 | – | 0.98% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |